🇺🇸 FDA

Intelligence Platform

Patents

Browse 822 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12195773

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186384

Compositions and methods for making and using thermostable immunogenic formulations with i

The Regents of the University of Colorado, a Body Corporate · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178860

Hyaluronidase enzyme formulations for high volume administration

HALOZYME, INC. · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180084

Cerium (III) carbonate formulations

The Regents of the University of California · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12178861

Stabilized liquid and lyophilized ADAMTS13 formulations

Takeda Pharmaceutical Company Limited · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173029

Antiviral prodrugs, pharmaceutical formulations, and methods

The Regents of the University of California · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171750

Isoxazoline parasiticide formulations and methods for treating blepharitis

Tarsus Pharmaceuticals, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168013

Antiviral prodrugs and nanoformulations thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161643

Stable formulations of SHR0302

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156883

Bisphosphocin gel formulations and uses thereof

Lakewood Amedex, Inc. · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156897

Magnesium-containing oxytocin formulations and methods of use

TONIX PHARMA LIMITED · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152262

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144812

Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators

Corcept Therapeutics Incorporated · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12133914

Hydrocortisone oral liquid formulations

Eton Pharmaceuticals, Inc. · Granted Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128092

Lyophilized factor IX formulations

BIOVERATIV THERAPEUTICS INC. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12128109

Muscle targeting complexes and formulations for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12123035

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115149

Formulations, methods, kits, and dosage forms

MedRegen, LLC · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115254

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115255

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12110520

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12104185

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12104184

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12102637

Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary

Neurocrine Biosciences, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted